AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06069570 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB-GDT-01
Description: KB-GDT-01 is an allogeneic, gamma delta T-cell suspension product manufactured from the isolation of healthy donor peripheral blood mononuclear cells (PBMC). The KB-GDT-01 cells are cryopreserved in vapor phase liquid nitrogen (LN2) in 50 mL CryoMACS® cryobags for a total of 200 × 106 viable cells/bag. The KB-GDT-01 cryopreserved product is thawed and administered intravenously (IV) until the entire bag is infused by gravity. Low dose radiotherapy (LDRT) will be administered to selected tumor sites (maximum of 5 isocenters) at 1.0 Gy/fraction on Days 1 and 2, followed by the KB-GDT-01 IV infusion on Day 3. LDRT will be repeated on Days 8 and 9, and the 2nd KB-GDT-01 IV infusion on Day 10.
Study NCT05558579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No sling use
Description: Patients will not use standard of care sling
Study NCT04910620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo only
Study NCT04910620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCI378
Description: TCI378 (Lactobacillus plantarum TCI378)
Study NCT04910620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCI507
Description: TCI507 (Lactobacillus plantarum TCI507)
Study NCT05393492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy and Radically Open dialectical behavior therapy
Description: Dialectical Behavior Therapy is a third wave cognitive-behavioral therapy. It focuses on emotional dysregulation and interactions between the patient and his family in genesis and maintenance of challenging behaviors. It is used here in an adapted form for cognitive problems.~Delivered in a group format of 19 weeks + individual sessions.
Study NCT05807594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HMZ 2.0 Intervention
Description: The intervention may be adapted such that a woman receives more support with each adaptation (only women who need added support to regulate GWG will receive adaptation). The model-based predictive control system in the HMZ 2.0 digital platform will continually and automatically evaluate GWG, identify when a woman may exceed GWG guidelines, and recommend an adaptation. The registered dietitian will review the data and behavior strategies that are suggested (guided PA workouts, EI cooking demonstrations, customized grocery planning, portion size control, food scales, and meal replacements). Practical, easy-to-adopt examples will be provided (walking in 5-10 min increments throughout the day to increase PA kcal, reduce sitting by 5 min/hour; replace 8 oz of whole milk with skim milk to reduce EI kcal) to facilitate behavior change while adhering to safety standards. Each woman's unique preferences and past successes with strategies are also considered when personalizing the dosage.
Study NCT05807594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Intervention
Description: Consistent with guidelines for comparator groups, all women will receive prenatal care offered by recruitment sites with routine provider visits, counseling about prenatal behaviors (e.g., no smoking), and clinical oversight of health. Women randomized to the attention control group will complete the same measurement procedures as the intervention group.
Study NCT04803565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made shoe insole
Description: Subjects will receive a custom-made shoe insole designed on the patient's foot and shoes. The subjects should wear the insole for at least 6 hours per day.
Study NCT04803565 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham conventional Insole
Description: Subjects will receive a conventional insole without any specific property (sham insole)
Study NCT06428643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlamydia, gonorrhea, syphilis, and HIV screening
Description: Individuals aged 15-26 years old will be tested for chlamydia, gonorrhea, HIV, and syphilis at community based venues. Individuals who test positive for chlamydia and gonorrhea and their sexual partners will be offered expedited treatment at participating pharmacies. Individuals who test positive will be asked to be rescreened for Ct/GC at 3 months post treatment.
Study NCT06134882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Monetary incentives are delivered via reloadable debit card based on verified engagement in target behaviors, including drug abstinence, appointment attendance, and completion of self-paced cognitive behavior therapy modules.
Study NCT06134882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy Modules
Description: Self-paced cognitive-behavior therapy modules delivered via smartphone.
Study NCT06134882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Contingency Management (CM) Guide
Description: Peer supports delivered via telehealth. Support is informed by the community reinforcement approach and includes motivational interviewing
Study NCT06134882 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Drug testing
Description: Self-performed salivary drug testing with incentives contingent upon proper completion of test procedures as confirmed by video.
Study NCT06134882 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wellness modules
Description: Basic health and wellness information delivered via self-paced learning modules.
Study NCT06134882 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Peer technical support
Description: Peer support for promoting engagement and addressing technical issues delivered via a mobile digital platform.
Study NCT04618094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bicycle ergometer training with different intensities
Description: Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
Study NCT06110078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Oral rinse with acetazolamide (not taken orally)
Study NCT06110078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetazolamide
Description: Oral rinse with acetazolamide (not taken orally)
Study NCT04618094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bicycle ergometer training with different intensities
Description: Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
Study NCT05158595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming low intensity group
Description: wobble board-based Exergame balance training, the game intensity will be low for this group (Size of goal will be kept small for 3 times a week, 30 minutes per day for 8 weeks.
Study NCT05158595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming moderate intensity group
Description: Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept medium).for 3 times a week, 30 minutes per day for 8 weeks.
Study NCT05158595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming high intensity group
Description: Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept high).for 3 times a week, 30 minutes per day for 8 weeks.
Study NCT05158595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group exergaming
Description: Exer games training with soccer heading and penguin slide games(Wii Fitt balance games) for 3 times a week, 30 minutes per day for 8 weeks.
Study NCT06164054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Rehabilitation System
Description: Participants of the experimental group will undergo treatment with Virtual Reality, both IVR and HB. The intervention will consist of 12 sessions lasting about 1 hour each and carried out with a frequency of three days per week within four weeks. Before starting the rehabilitation, arm illusion with the Handbox is inducted to explore the ability of the patients to perceive the virtual arm as their own. During this task, patients sit on a chair with the injured arm inside the Handbox and are invited to perform slow movements with the hand, such as moving the fingers one at a time and moving the wrist up and down. Moreover, they are invited to keep their attention to the virtual arm project on the screen that follows their natural movements. The arm illusion lasts 3 minutes, and the embodiment questionnaire is administered. Then, the treatment starts with IVR and HB sessions, which are counterbalanced to avoid the learning effect
Study NCT06164054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional therapy
Description: Participants randomly assigned to the control group will receive rehabilitation treatment as per usual clinical practice. Specifically, patients will be directed to rehabilitation facilities according to standard clinical rehabilitation pathways. They will be assigned to a physiotherapist who will administer the rehabilitation treatment for the upper limb impairment. Patients in the control group will receive the same amount of rehabilitation for the recovery of upper limb impairment as the treatment group, which means 3 physiotherapy sessions lasting 1 hour 3 times a week for 4 weeks.
Study NCT04932148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental HD
Description: Starting haemodialysis at twice weekly frequency
Study NCT04932148 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional HD
Description: Starting haemodialysis at thrice weekly frequency
Study NCT04947189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seviteronel-D (Seivteronel in combination with dexamethasone)
Description: Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.
Study NCT04947189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Use of docetaxel chemotherapy for solid tumours
Study NCT04602845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 50ug Fentanyl intravenously
Study NCT04602845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 50ug Fentanyl intravenously
Study NCT04602845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: 50mg Fentanyl intravenously
Study NCT04602845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: 50mg Fentanyl intravenously
Study NCT04602845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 2.5mg midazolam in 2ml normal saline intravenously
Study NCT04602845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 3mg Remimazolam in 2ml normal saline intravenously
Study NCT05904483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFA
Description: PFA
Study NCT04648020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine HCl Mucoadhesive Buccal Tablet
Description: 100 μg of clonidine per tablet
Study NCT04648020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mucoadhesive Buccal Tablet
Description: Placebo
Study NCT06375148 — intervention group
Intervention type: OTHER
Intervention: Enteral nutrition
Description: prone position ventilation
Study NCT05212207 — intervention group
Intervention type: OTHER
Intervention: CGM, smartwatch, and electronic diary
Description: Participants wear a CGM and a smartwatch while keeping an electronic diary with information such as meals, sleep, and activity.
Study NCT01596426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sancuso
Description: granisetron transdermal system
Study NCT01596426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV granisetron
Description: IV granisetron
Study NCT05076851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo+ADT（Androgen Deprivation Therapy） ，Route of placebo administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
Study NCT05076851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxalutamide
Description: Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
Study NCT06465667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dashboard
Description: The Dashboard intervention, representing current standard of care, will consist of a standard e-mail message with a link to the dashboard and text explanation. No performance data will be included in the e-mail, and links will not be monitored for clickthrough with repeat e-mail.
Study NCT06465667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precision Feedback Push
Description: The experimental intervention, precision feedback e-mail messaging, will consist of an e-mail with a link to the dashboard along with tailored information about a participant's performance in the quality process measure of interest. For example, e-mail subject lines may read You have room for improvement in stent omission, accompanied by a visual display in the body of the e-mail showing a participant's performance relative to a top performing peer. The behavior change intervention delivery component will also involve modifications to existing procedures. Namely, performance feedback will be reported directly in the e-mail as either plain text, or an embedded or attached image with graphed data.
Study NCT04908982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81mg
Description: 81mg aspirin daily beginning between 12 and 16 weeks of pregnancy and continuing until delivery.
Study NCT05097430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-focused brief intervention
Description: The primary intervention component is the Check Your Drinking (CYD) intervention - an electronically-delivered brief intervention designed to assess and provide personalized feedback regarding the quantity, frequency, and severity of one's alcohol consumption. Additionally, intervention condition participants who are identified as having a concurrent substance use concern or who may be experiencing depression will receive information about local resources that can assist with such concerns.
Study NCT05547984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Mobility Cup
Description: Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the Dual Mobility cup
Study NCT05547984 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Acetabular component
Description: Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the standard device with polyethylene + vitamin E inlay and metal head
Study NCT05543317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT
Description: Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-RGD, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
Study NCT06631300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: A prednisone taper will be given to the subjects as follows: prednisone 40mg for 3 days, prednisone 30mg for 3 days, prednisone 20mg for 3 days, prednisone 10mg for 3 days, prednisone 5mg for 3 days, then off for a total of 15 days.
Study NCT06631300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo taper will be given to match the same number of pills administered in each stage of the prednisone taper.
Study NCT06629415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: injecting 7.5 mg (3 ml of a 25 mg/10 ml solution) intravenously in the pre-operative holding area at least 20 minutes before surgery.~Before dissecting the adhesions surrounding the hepatoduodenal ligament, fluorescence cholangiography (FC) is carried out to determine the anatomy of the extrahepatic bile ducts by converting the full-color images to fluorescence images using filter switches on the camera head and/or light source in the laparoscopic imaging system (Fig. 1). The \&amp;#34;critical view of safety\&amp;#34; is then reached by dissecting Calot\&amp;#39;s triangle and using FC to verify whether the accessory bile ducts are present or absent throughout the procedures. It is necessary to acquire fluorescence image
Study NCT06629415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green Drug
Description: 1.25 mg of ICG powder was dissolved in 3 cm of saline, and the concentration was roughly 0.04 mg after each 1 cm of saline was diluted by 9 cm of saline. In order to prevent dye leakage that might result in false FC results, a veress needle was inserted through the abdominal wall and into the gall bladder fundus through the liver bed. The puncture site was then cauterized.
Study NCT06268847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~2 capsules per day for 90 days of placebo.
Study NCT06268847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACT01
Description: 2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
Study NCT06268847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACT02
Description: 2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
Study NCT05887908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-administration of cefepime and nacubactam
Description: 2 g cefepime and 1 g nacubactam
Study NCT05887908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-administration of aztreonam and nacubactam
Description: 2 g aztreonama and 1 g nacubactam
Study NCT05887908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipenem/cilastatin
Description: 1 g imipenem/1 g cilastatin
Study NCT05503277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LTSD
Description: measuring seal pressure
Study NCT05503277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel
Description: measuring seal pressure
Study NCT06209619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06209619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06209619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT06209619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Given PO
Study NCT06209619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06209619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT05586776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% Chlorhexidine Gluconate
Description: Used for daily showering/bathing for 30 days after hospital discharge.
Study NCT05586776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Mupirocin
Description: Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
Study NCT05586776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Soap Without Antiseptic Properties (Placebo)
Description: Used for daily showering/bathing for 30 days after hospital discharge.
Study NCT05586776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Ointment
Description: Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
Study NCT05352282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: SAPB will be done preoperative before induction of anesthesia under songraphic guidance and aseptic conditions with the patient in the lateral position, with the side of the surgical side up and the upper limb hanging over the patient's head. The ribs will be then counted, and when the 5th rib is identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane. The ribs, pleura, overlying serratus muscle and latissimus dorsi muscle will be identified, and the needle will be advanced cephalic in-plane until the tip reaches the plane between the serratus anterior and latissimus dorsi. Afterward, 2 mL dextrose 5% will be injected; then, 30 mL of bupivacaine 0.25% will be injected in the plane between the serratus anterior and latissimus dorsi.